Impact of PD-L1 overexpression on immune checkpoint inhibitor efficacy in triple-negative breast cancer using a 4T1 murine model.
RNA-seq (gene expression) · mouse · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 12 samples: 12 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Impact of PD‑L1 upregulation on immune checkpoint inhibitor efficacy in triple‑negative breast cancer using a 4T1 murine modelInternational journal of oncology · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE292013_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1234857 and SRA study SRP570338. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 12 sample titles: 12 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8846476 4T1 control tumor treated with IgG (Sample 1)
- GSM8846477 4T1 control tumor treated with IgG (Sample 2)
- GSM8846478 4T1 control tumor treated with IgG (Sample 3)
- GSM8846479 4T1 control tumor treated with anti-PD-L1 (Sample 1)
- GSM8846480 4T1 control tumor treated with anti-PD-L1 (Sample 2)
- GSM8846481 4T1 control tumor treated with anti-PD-L1 (Sample 3)
- GSM8846482 4T1 PD-L1 overexpressed tumor treated with IgG (Sample 1)
- GSM8846483 4T1 PD-L1 overexpressed tumor treated with IgG (Sample 2)
- GSM8846484 4T1 PD-L1 overexpressed tumor treated with IgG (Sample 3)
- GSM8846485 4T1 PD-L1 overexpressed tumor treated with anti-PD-L1 (Sample 1)
- GSM8846486 4T1 PD-L1 overexpressed tumor treated with anti-PD-L1 (Sample 2)
- GSM8846487 4T1 PD-L1 overexpressed tumor treated with anti-PD-L1 (Sample 3)
- GSE278396 Cathepsin L as a dual-target to mitigate muscle wasting while enhancing anti-tumor efficacy of anti-PD-L1 [Bulk2] 15 samples shares pd-l1, efficacy
- GSE310210 Berry-derived gold nanoparticles induce integrated oxidative stress-mediated apoptosis, immune modulation, and transcriptomic remodeling in 4T1 triple-negative cancer cells 15 samples shares 4t1, triple-negative
- GSE278013 Cathepsin L as a dual-target to mitigate muscle wasting while enhancing anti-tumor efficacy of anti-PD-L1 [Bulk1] 14 samples shares pd-l1, efficacy
- GSE332663 Transcriptomic profiling of Cosmc-silenced Tn+ 4T1 cells-bearing triple-negative tumors in mice 12 samples shares 4t1, triple-negative
- GSE271663 Tumor-Suppressing Multi-Enterobacteria enhance the anti-PD-1/PD-L1 efficacy in microsatellite stable colorectal cancer 36 samples shares pd-l1, efficacy
- GSE252597 Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment eradicating colorectal liver metastases 24 samples shares overexpression, checkpoint
- GSE276098 Immunosuppressive microenvironment restrains chemotherapy efficacy in liver metastases of triple-negative breast cancer 16 samples shares triple-negative, efficacy
- GSE317281 Integrated bulk and single-cell transcriptome analysis reveals the impact of cyclophosphamide on tumor microenvironment in triple-negative breast cancer models 14 samples shares triple-negative, impact
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.